Osteoarthritis: NSAIDs for Pain Relief - Guidelines-Based Review

1. Background: Why NSAIDs Work in OA

• Firestein & Kelley's Textbook of Rheumatology, p. 9015-9031

2. Indications

• Topical agents (first preference for localized knee/hand OA, especially in older adults or those with GI/CV risk) have failed or when disease is more widespread
• Moderate-to-severe joint pain unresponsive to acetaminophen, exercise, weight loss, or physical therapy
• Flares of OA pain requiring short-term systemic analgesia
• Patients with significant inflammatory component (morning stiffness, joint swelling)

• ACR/AF 2019 OA Guidelines; Nonoperative Management Recommendations for Knee OA, PMC 2025

3. NSAID Selection & Doses

• Naproxen is preferred when CV risk is a concern (most cardiovascular-neutral among oral NSAIDs), combined with a PPI
• Celecoxib (COX-2 selective) is preferred when GI risk is the main concern, though it increases CV risk
• Topical diclofenac (1% gel) is preferred in elderly and those with GI or renal concerns - equivalent efficacy, much lower systemic absorption

4. Risk-Stratified Prescribing (Firestein & Kelley Framework)

• Firestein & Kelley's Textbook of Rheumatology, block 14, p. 141-168

5. Duration of Therapy

• Goal: shortest effective duration - use NSAIDs intermittently for pain flares rather than continuously
• Anti-inflammatory/analgesic effect peaks at 2 weeks, begins declining by 8 weeks
• GI adverse events increase significantly as early as 4 weeks after initiation
• For chronic OA: use intermittent "as-needed" dosing where possible; reassess need at each visit
• Do not use extended-release formulations in high-risk patients
• If ongoing pain control is needed despite multiple risk factors, consider alternative agents (duloxetine, tramadol) or intra-articular injections

6. Monitoring

Baseline (before starting)

• BP - NSAIDs cause sodium retention, fluid retention, and can raise BP or worsen heart failure
• Renal function (creatinine, eGFR) - NSAIDs reduce renal prostaglandins, can precipitate AKI especially in the elderly, dehydrated, or those with CKD
• Liver function - baseline ALT/AST
• CBC - particularly if prolonged use anticipated
• GI history - prior peptic ulcer, GI bleed
• Cardiovascular history - prior MI, stroke, heart failure

Ongoing Monitoring

Special Populations Requiring Extra Caution

• Elderly - substantially higher risk of GI bleed, renal impairment, and heart failure exacerbation; prefer topical NSAIDs or acetaminophen
• CKD - avoid or use with great caution; monitor creatinine closely; NSAIDs can cause acute tubular necrosis and hyperkalemia
• Heart failure - NSAIDs can worsen fluid retention and precipitate decompensation
• Anticoagulant/antiplatelet users - significantly increased bleeding risk
• Elderly (>65) on NSAIDs: PPI co-prescription is mandatory to reduce GI risk
• Harrison's Principles of Internal Medicine 22E, p. 2239; Firestein & Kelley, p. 9015-9038

7. Contraindications to NSAIDs in OA

• Active peptic ulcer or recent GI bleed
• Severe renal impairment (eGFR <30 mL/min)
• Severe hepatic impairment
• History of aspirin/NSAID-induced asthma or urticaria
• Third trimester of pregnancy
• Severe heart failure (NYHA Class III-IV)
• Recent CABG (first 10-14 days post-op)

8. Radiographic (X-ray) Findings in OA

1. Joint Space Narrowing (Loss of Cartilage)

2. Osteophyte Formation

3. Subchondral Changes

• Subchondral sclerosis (increased bone density adjacent to the joint surface due to osteoblastic activity)
• Subchondral cysts (geodes) - formed by synovial fluid entering the bone through damaged cartilage

4. Joint Deformity and Loose Bodies

• Ligamentous laxity with joint malalignment (varus in medial knee OA)
• Intra-articular loose bodies (osteochondral fragments that may calcify and enlarge)

• Grainger & Allison's Diagnostic Radiology, p. 1113-1114

Site-Specific X-Ray Patterns

9. Step-Up Treatment Ladder (Guideline Summary)

Step 1 (non-pharmacologic): Exercise, weight loss, physiotherapy, patient education
    ↓
Step 2 (topical): Topical NSAIDs (diclofenac 1% gel), topical capsaicin
    ↓
Step 3 (oral): Acetaminophen 500mg-1g TID (limited evidence but low risk)
    ↓
Step 4 (oral NSAID): Lowest effective dose, shortest duration, with GI/CV risk stratification
    ↓
Step 5 (adjuncts): Duloxetine (SNRi), tramadol (weak opioid)
    ↓
Step 6 (intra-articular): Corticosteroid injections (short-term flares), hyaluronic acid
    ↓
Step 7 (surgical): Joint replacement when conservative measures fail

10. Recent Evidence Update (PubMed 2023-2025)